Shopping Cart 0
Cart Subtotal
USD 0

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Pipeline Review, H2 2018

Summary

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Immunology and Respiratory which include indications Gastric Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Small Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Allergic Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Breast Cancer, Cervical Cancer, Colorectal Cancer, Epithelial Tumor, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Breast Cancer, Mycosis Fungoides, Nasopharyngeal Cancer, Non-Hodgkin Lymphoma, Ovarian Cancer, Renal Cell Carcinoma, Sezary Syndrome, Spinal Cord Disorders, T-Cell Leukemia, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Tropical Spastic Paraparesis.

The latest report C-C Chemokine Receptor Type 4-Pipeline Review, H2 2018, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

- The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects

- The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Overview

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Companies Involved in Therapeutics Development

Corion Biotech Srl

FLX Bio Inc

Kyowa Hakko Kirin Co Ltd

Tizona Therapeutics Inc

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Drug Profiles

AT-008-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBChMF-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-193-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-475-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mogamulizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CCR4 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Discontinued Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Product Development Milestones

Featured News & Press Releases

Sep 27, 2018: FLX Bio announces first patient dosed with FLX475, a best-in-class CCR4 inhibitor for the treatment of multiple cancers

Sep 21, 2018: Kyowa Kirin announces Mogamulizumab received positive CHMP opinion for the treatment of Mycosis Fungoides and Sezary Syndrome

Aug 29, 2018: New therapy for rare lymphoma

Aug 21, 2018: Kyowa Hakko Kirin receives the partial change approval of POTELIGEO in Japan

Aug 13, 2018: Kyowa Kirin reports positive results from MAVORIC study

Aug 10, 2018: FDA approves Kyowa Kirin's Poteligeo to treat two lymphoma types

Jun 04, 2018: Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO

May 30, 2018: Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab

Apr 12, 2018: FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting

Dec 11, 2017: Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

Nov 30, 2017: Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan

Nov 28, 2017: Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab's Biologics License Application

Oct 27, 2017: Kyowa Hakko Kirin Announces Marketing Authorization Application for Mogamulizumab Validated by European Medicines Agency

Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate

Aug 25, 2017: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sezary Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Corion Biotech Srl, H2 2018

Pipeline by FLX Bio Inc, H2 2018

Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Pipeline by Tizona Therapeutics Inc, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Therapeutic Products under Development, Key Players in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Therapeutics, C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Pipeline Overview, C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Pipeline, C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Pipeline Assessment


Companies

Corion Biotech Srl

FLX Bio Inc

Kyowa Hakko Kirin Co Ltd

Tizona Therapeutics Inc